Early Success Reported in hESC Trial for Macular Degeneration
BioWorld Today Correspondent
LONDON – The first patient in the first human embryonic stem cell (hESC) trial to be held in Europe left Moorfields Eye Hospital in London on Monday after being treated for macular degeneration. At the same time, Advanced Cell Technology (ACT) Inc., the company behind the trial of the hESC-derived retinal pigment epithelium cells published initial clinical data on the U.S. arm of the study, showing tantalizing early signs of efficacy.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST